SPM-0404 / Sea Pharmaceuticals - LARVOL DELTA

Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders (ACCESSWIRE) - "Inotiv Inc will assist Sea to quantify SPM-0404 levels in Clinical Phase 1 and Ph.1b Trials...Sea Pharmaceuticals, LLC...announced its selection of Inotiv Inc...for pre-clinical development IND-enabling studies to support the advancement of Sea's lead molecule SPM-0404 as a potential new oral medicine to treat tinnitus, epilepsy and S-ALS. Sea's SPM-0404 and a second-generation molecule SPM-0606 represent a portfolio strategy of discovery and development of potent, selective, CNS-penetrant molecules targeting excitatory glutamate neurotransmission."

Commercial • Amyotrophic Lateral Sclerosis • Epilepsy

Sea Pharmaceuticals Advancing Oral Neurotherapeutics as Potential Medicines for Tinnitus, Epilepsy, and ALS in Collaboration with TCG GreenChem (ACCESSWIRE) - "Sea Pharmaceuticals, LLC...today announced the advancement of two orally-administered neurotherapeutic molecules as potential new medicines for high need neurological disorders. Sea's lead molecule SPM-0404 and a second-generation molecule SPM-0606 are part of a portfolio strategy of discovery and development of novel, potent, selective oral compounds targeting the glutamate pathway...Sea also announced today a strategic collaboration with TCG GreenChem, Inc. of Ewing NJ USA (TCG GC) who will conduct chemical development for Sea on lead molecule SPM-0404 producing the cGMP material (current good manufacturing practices) for IND-enabling studies and for Clinical Trials."

Pipeline update • Amyotrophic Lateral Sclerosis • CNS Disorders